Longitudinal effect of disease‐modifying therapy on left ventricular diastolic function in children with sickle cell anemia
American Journal of Hematology · 2023-06 · 98 (6) · 838-847
DOI: 10.1002/ajh.26911 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 20.03.2023. Verfasst von Parul Rai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Hematology, St Jude Children's Research Hospital, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Ventricular Dysfunction, Left. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Cardiac abnormalities seen in sickle cell anemia (SCA) include diastolic dysfunction, which has been shown to be associated with high morbidity and early mortality. The effect of disease‐modifying therapies (DMT) on diastolic dysfunction is poorly understood. We prospectively evaluated the effects of hydroxyurea and monthly erythrocyte transfusions on diastolic function parameters over 2 years. A total of 204 subjects with HbSS or HbSβ0‐thalassemia (mean age 11 ± 3.7 years), unselected for disease severity, had diastolic function assessed with surveillance echocardiograms twice, 2 years apart. During this 2‐year observation period, 112 participants received DMTs (hydroxyurea, n = 72, monthly erythrocyte transfusions, n = 40), 34 initiated hydroxyurea, and 58 did not receive any DMT. The entire cohort showed an increase in left atrial volume index (LAVi) of 3.40 ± 10.86 mL/m2, p = .001 over 2 years. This increase in LAVi was independently associated with anemia, high baseline E/e′ or LV dilation. Individuals not exposed to DMT were younger (mean age 8.8 ± 2.9 years), but at baseline their prevalence of abnormal diastolic parameters was similar to that of the DMT‐exposed participants who were older (mean age 12 ± 3.8 years). Participants on DMTs saw no improvement in diastolic function over the study period. In fact, participants on hydroxyurea saw a possible worsening in diastolic parameters (14% increase in LAVi and ~5% decrease in septal e′) but also a ~9% decrease in fetal hemoglobin (HbF) levels. Further studies are needed to evaluate if exposure to DMT for a longer duration or achieving higher HbF might be beneficial in alleviating diastolic dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Hematology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Division of Pediatric Cardiology, University of Tennessee College of Medicine, Memphis, Tennessee, USA.
- Cardiology consultants, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
ORCID-Profile: Parul Rai, Jane S Hankins
Zitieren
APA
Rai, P., Okhomina, V. I., Kang, G., Martinez, H. R., Hankins, J. S., & Joshi, V. (2023). Longitudinal effect of disease‐modifying therapy on left ventricular diastolic function in children with sickle cell anemia. American Journal of Hematology, 98(6), 838-847. https://doi.org/10.1002/ajh.26911
Vancouver
Rai P, Okhomina VI, Kang G, Martinez HR, Hankins JS, Joshi V. Longitudinal effect of disease‐modifying therapy on left ventricular diastolic function in children with sickle cell anemia. American Journal of Hematology. 2023;98(6):838-847. doi:10.1002/ajh.26911
BibTeX
@article{Rai2023,
author = {Rai, Parul and Okhomina, Victoria I and Kang, Guolian and Martinez, Hugo R and Hankins, Jane S and Joshi, Vijaya},
title = {Longitudinal effect of disease‐modifying therapy on left ventricular diastolic function in children with sickle cell anemia},
journal = {American Journal of Hematology},
year = {2023},
volume = {98},
number = {6},
pages = {838--847},
doi = {10.1002/ajh.26911}
}
EUVIMED